ADMA Biologics (ADMA) Misses Q2 EPS by 1c

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $121.98 million versus the consensus estimate of $124.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• Keurig Dr Pepper (KDP) PT Raised to $39 at Bernstein SocGen Group
• Trump on Iran: may be a big attack, may take Kharg, may put back blockade